149 related articles for article (PubMed ID: 26245495)
1. Comparing the costs of three prostate cancer follow-up strategies: a cost minimisation analysis.
Pearce AM; Ryan F; Drummond FJ; Thomas AA; Timmons A; Sharp L
Support Care Cancer; 2016 Feb; 24(2):879-886. PubMed ID: 26245495
[TBL] [Abstract][Full Text] [Related]
2. Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data.
Molinier L; Castelli C; Bauvin E; Rebillard X; Soulié M; Daurès JP; Grosclaude P
Eur J Health Econ; 2011 Aug; 12(4):363-71. PubMed ID: 20549536
[TBL] [Abstract][Full Text] [Related]
3. Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.
Lord J; Willis S; Eatock J; Tappenden P; Trapero-Bertran M; Miners A; Crossan C; Westby M; Anagnostou A; Taylor S; Mavranezouli I; Wonderling D; Alderson P; Ruiz F
Health Technol Assess; 2013 Dec; 17(58):v-vi, 1-192. PubMed ID: 24325843
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
[TBL] [Abstract][Full Text] [Related]
5. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L
CMAJ; 2000 Apr; 162(7):987-92. PubMed ID: 10763396
[TBL] [Abstract][Full Text] [Related]
6. Estimating the healthcare costs of treating prostate cancer in Australia: A Markov modelling analysis.
Gordon LG; Tuffaha HW; James R; Keller AT; Lowe A; Scuffham PA; Gardiner RA
Urol Oncol; 2018 Mar; 36(3):91.e7-91.e15. PubMed ID: 29169847
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Practice Patterns Among Oncologists Participating in the Oncology Care Model.
Walker B; Frytak J; Hayes J; Neubauer M; Robert N; Wilfong L
JAMA Netw Open; 2020 May; 3(5):e205165. PubMed ID: 32421185
[TBL] [Abstract][Full Text] [Related]
8. Urologist Practice Structure and Spending for Prostate Cancer Care.
Modi PK; Herrel LA; Kaufman SR; Yan P; Borza T; Skolarus TA; Schroeck FR; Hollenbeck BK; Shahinian VB
Urology; 2019 Aug; 130():65-71. PubMed ID: 31029672
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors: potential cost reductions by applying prescribing guidelines.
Cahir C; Fahey T; Tilson L; Teljeur C; Bennett K
BMC Health Serv Res; 2012 Nov; 12():408. PubMed ID: 23163956
[TBL] [Abstract][Full Text] [Related]
10. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis.
Keegan KA; Dall'Era MA; Durbin-Johnson B; Evans CP
Cancer; 2012 Jul; 118(14):3512-8. PubMed ID: 22180322
[TBL] [Abstract][Full Text] [Related]
11. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Jan; 65(1):124-37. PubMed ID: 24207135
[TBL] [Abstract][Full Text] [Related]
12. Cumulative cost pattern comparison of prostate cancer treatments.
Wilson LS; Tesoro R; Elkin EP; Sadetsky N; Broering JM; Latini DM; DuChane J; Mody RR; Carroll PR
Cancer; 2007 Feb; 109(3):518-27. PubMed ID: 17186528
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes.
Butt T; Lee A; Lee C; Tufail A;
BMJ Open; 2015 May; 5(5):e006535. PubMed ID: 25943370
[TBL] [Abstract][Full Text] [Related]
14. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).
Faria R; Soares MO; Spackman E; Ahmed HU; Brown LC; Kaplan R; Emberton M; Sculpher MJ
Eur Urol; 2018 Jan; 73(1):23-30. PubMed ID: 28935163
[TBL] [Abstract][Full Text] [Related]
15. Clinical practice guidelines and the cost of care. A growing alliance.
O'Brien JA; Jacobs LM; Pierce D
Int J Technol Assess Health Care; 2000; 16(4):1077-91. PubMed ID: 11155829
[TBL] [Abstract][Full Text] [Related]
16. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer.
Panebianco V; Valerio MC; Giuliani A; Pecoraro M; Ceravolo I; Barchetti G; Catalano C; Padhani AR
Eur Urol Oncol; 2018 Aug; 1(3):208-214. PubMed ID: 31102623
[TBL] [Abstract][Full Text] [Related]
18. Costs Associated With Imaging Surveillance After Treatment for Head and Neck Cancer.
Nocon CC; Kennedy A; Jaffe J; Pruitt J; Kuchta K; Bhayani MK
JAMA Otolaryngol Head Neck Surg; 2021 Jul; 147(7):632-637. PubMed ID: 33983375
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the cost-effectiveness of anterior uveitis investigation by Canadian ophthalmologists.
Noble J; Hollands H; Forooghian F; Yazdani A; Sharma S; Wong DT; Derzko-Dzulynsky L
Can J Ophthalmol; 2008 Dec; 43(6):652-7. PubMed ID: 19020630
[TBL] [Abstract][Full Text] [Related]
20. [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].
Reinhold T; Dornquast C; Börgermann C; Weißbach L
Urologe A; 2016 Dec; 55(12):1573-1585. PubMed ID: 27822603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
